Mechelen, Belgium;  30  June 2009  -  Galapagos NV  (Euronext:  GLPG)
announces  that  it  has  been  granted  the  Innovative   Enterprise
qualification (Entreprises  Innovantes au  titre des  FCPI) from  the
French governmental organization  OSEO that  supports innovation  and
growth of SMEs.   French private  investors are  eligible to  receive
significant tax advantages for participating in funds which invest in
FCPI qualified companies such as Galapagos.

Innovation-focused mutual  funds (FCPI)  were created  by the  French
1997 Finance Act in  order to support  the development of  innovative
small firms in France.  The Act  has since been extended and  amended
to increase the tax  benefits gained from  holding FCPI units.   FCPI
funds are  subject to  approval  and audit  by the  French  financial
markets authority AMF.  Since its inception in 1997, €4.4 billion has
been raised by FCPI funds.

"Following the  OSEO's rigorous  review process,  Galapagos has  been
recognized as the type of innovative company the French government is
looking  to  support  and  stimulate,"  said  Onno  van  de   Stolpe,
Galapagos' CEO.  "We are pleased  that the acquisition of our  French
research center in 2006  has brought this  additional benefit to  the
Galapagos  Group.   Through  this  qualification,  Galapagos  is  now
eligible for investments by FCPI funds, opening the opportunity to  a
new category of French institutional investors."

About OSEO
OSEO  was  created  in  2005  by  bringing  together  ANVAR   (French
Innovation Agency)  and BDPME  (Development Bank  for SMEs).   OSEO's
mission is to provide assistance and financial support to French SMEs
in  the  most  decisive  phases  of  their  life  cycle:  start   up,
innovation, development, business transfer/buy  out.  By sharing  the
risk, OSEO facilitates  the access  of SMEs to  financing by  banking
partners and equity capital investors.  More info at: www.oseo.fr.

About Galapagos
Galapagos   (Euronext: GLPG;  OTC:  GLPYY) is  a drug  discovery  and
development company with  small molecule programs  in bone and  joint
diseases, bone  metastasis, cachexia,  anti-infectives and  metabolic
diseases.  It  has  established  risk  sharing  alliances  with  GSK,
Janssen Pharmaceutica, Eli Lilly and Merck.  Through an alliance with
MorphoSys, Galapagos  is also  developing new  antibody therapies  in
bone and joint  diseases.  Its  division BioFocus DPI  offers a  full
suite  of   target-to-drug  discovery   products  and   services   to
pharmaceutical and  biotech  companies and  to  patient  foundations,
encompassing target  discovery  and validation,  screening  and  drug
discovery through to delivery of pre-clinical candidates.   Galapagos
currently  employs  490  people   and  operates  facilities  in   six
countries, with global headquarters in Mechelen, Belgium.  More  info
at: www.glpg.com.


CONTACT
Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 62 291 6240
ir@glpg.com


This  release  may  contain  forward-looking  statements,  including,
without  limitation,  statements  containing  the  words  "believes,"
"anticipates," "expects," "intends,"  "plans," "seeks,"  "estimates,"
"may," "will,"  "could," "stands  to," and  "continues," as  well  as
similar expressions.  Such  forward-looking  statements  may  involve
known and unknown risks, uncertainties and other factors which  might
cause  the  actual  results,  financial  condition,  performance   or
achievements of  Galapagos, or  industry  results, to  be  materially
different from any historic or future results, financial  conditions,
performance  or   achievements   expressed   or   implied   by   such
forward-looking statements. Given these uncertainties, the reader  is
advised not  to  place any  undue  reliance on  such  forward-looking
statements. These  forward-looking statements  speak only  as of  the
date of publication of  this document. Galapagos expressly  disclaims
any obligation to update any such forward-looking statements in  this
document to  reflect  any  change in  its  expectations  with  regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.